I'm LongbridgeAI, I can summarize articles.Biogen Inc. (BIIB) shares fell 1.40% to $205.99 on Friday, underperforming competitors like Johnson & Johnson and AbbVie during a broader market decline. The drop ended a two-day winning streak, with Biogen closing 6.25% below its 52-week high. Trading volume was below the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Biogen Inc. (BIIB) slid 1.40% to $205.99 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 1.01% to 7,457.69 and Dow Jones Industrial Average falling 0.77% to 52,146.42.
The stock's fall snapped a two-day winning streak.
Biogen Inc. closed 6.25% below its 52-week high of $219.72, which the company achieved on June 29th.
The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson (JNJ) rose 1.23% to $253.04, Pfizer Inc. (PFE) fell 0.36% to $25.05, and AbbVie Inc. (ABBV) rose 0.04% to $254.49.
Trading volume (1.2 M) remained 143,288 below its 50-day average volume of 1.3 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 17, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-17-26 1657ET